Genetic mutations and abnormal gene regulation are key mechanisms underlying
tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores …

Among the various immunological and non-immunological tumor-promoting activities of
myeloid-derived suppressor cells (MDSCs), their immunosuppressive capacity remains a …

Glioblastoma (GBM) is an incurable primary malignant brain cancer hallmarked with a
substantial protumorigenic immune component. Knowledge of the GBM immune …

Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for
relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune …

Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous
disease. Transcriptomic and genetic characterization of DLBCL has increased the …

PD-1, a T cell checkpoint receptor and target of cancer immunotherapy, is also expressed on
myeloid cells. The role of myeloid-specific versus T cell–specific PD-1 ablation on antitumor …

Epigenetic alterations play an important role in tumor progression of diffuse large B-cell
lymphoma (DLBCL). However, the biological relevance of epigenetic gene mutations on …

Purpose: The chimeric antigen receptor (CAR) T-cell therapy has been effective for patients
with CD19+ B-cell malignancies. Most studies have investigated the second-generation …

B-cell lymphoma is a group of hematological malignancies with high clinical and biological
heterogeneity. The pathogenesis of B-cell lymphoma involves a complex interaction …

Immune evasion is a key strategy adopted by tumor cells to escape the immune system
while promoting their survival and metastatic spreading. Indeed, several mechanisms have …